BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断

2019-10-19 不详 MedSci原创m

百时美施贵宝(Bristol-Myers Squibb)和辉瑞(Pfizer)两家药业巨头宣布,他们正在与Fitbit结盟,以帮助推动及时诊断房颤(AFib)。

百时美施贵宝(Bristol-Myers Squibb)和辉瑞(Pfizer)两家药业巨头宣布,他们正在与Fitbit结盟,以帮助推动及时诊断房颤(AFib)。

辉瑞生物制药集团总裁Angela Hwang说:"我们处在医疗保健的新纪元,不仅要专注开发治疗方法,而且着眼于技术和数据的潜力,以帮助患者更多地了解他们的健康状况。"

她继续说道:"我们对可穿戴设备以及与BMS和Fitbit的合作如何帮助患者和医生发现并了解心律不齐感到兴奋。"

AFib是最常见的不规则心跳类型,并且是中风的重要危险因素。由于它可能是无症状的,因此常常无法被发现,而且一些研究表明,患有中风的人中有25%以上是在中风后发现的。

已有的百时美施贵宝与辉瑞联盟致力于推动有关房颤和静脉血栓栓塞的教育和认识。通过与非营利组织的合作,该联盟旨在为患者、医师和决策者提供他们所需的信息,以了解中风和其他与心血管疾病相关的危险因素并采取适当的行动。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887282, encodeId=7927188e2821a, content=<a href='/topic/show?id=33971e181b8' target=_blank style='color:#2F92EE;'>#TBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17181, encryptionId=33971e181b8, topicName=TBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sat Jan 11 09:53:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953945, encodeId=c384195394575, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Feb 20 20:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700691, encodeId=a3bb1e0069116, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Sun Feb 23 21:53:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331955, encodeId=2384133195560, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2020-01-11 hxj0117
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887282, encodeId=7927188e2821a, content=<a href='/topic/show?id=33971e181b8' target=_blank style='color:#2F92EE;'>#TBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17181, encryptionId=33971e181b8, topicName=TBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sat Jan 11 09:53:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953945, encodeId=c384195394575, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Feb 20 20:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700691, encodeId=a3bb1e0069116, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Sun Feb 23 21:53:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331955, encodeId=2384133195560, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887282, encodeId=7927188e2821a, content=<a href='/topic/show?id=33971e181b8' target=_blank style='color:#2F92EE;'>#TBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17181, encryptionId=33971e181b8, topicName=TBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sat Jan 11 09:53:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953945, encodeId=c384195394575, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Feb 20 20:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700691, encodeId=a3bb1e0069116, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Sun Feb 23 21:53:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331955, encodeId=2384133195560, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887282, encodeId=7927188e2821a, content=<a href='/topic/show?id=33971e181b8' target=_blank style='color:#2F92EE;'>#TBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17181, encryptionId=33971e181b8, topicName=TBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sat Jan 11 09:53:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953945, encodeId=c384195394575, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Feb 20 20:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700691, encodeId=a3bb1e0069116, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Sun Feb 23 21:53:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331955, encodeId=2384133195560, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887282, encodeId=7927188e2821a, content=<a href='/topic/show?id=33971e181b8' target=_blank style='color:#2F92EE;'>#TBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17181, encryptionId=33971e181b8, topicName=TBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sat Jan 11 09:53:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953945, encodeId=c384195394575, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Feb 20 20:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700691, encodeId=a3bb1e0069116, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Sun Feb 23 21:53:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331955, encodeId=2384133195560, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Oct 21 06:53:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 canlab

相关资讯

市值935亿美元的BMS要卖?辉瑞罗氏诺华吉列德钱多到烧手……

据FiercePharma消息,进入2017年之后,BMS被多名分析师列入潜在并购标的推荐之中。他们为何会向药企客户提出可以考虑收购几乎在免疫肿瘤领域“称王称霸”的BMS?这是怎么回事?潜在买家中,辉瑞再次出现。结合之前收购阿斯利康出价1170亿美元,如果这次辉瑞真的出手,又会是个什么价格?可以比较的是,BMS市值比阿斯利康高出了整整300多亿美元,而且这家公司的核心产品可都是全球最热的免疫肿瘤类

ACC 2012:口服抗炎药减少BMS支架内晚期丢失

  2012年3月24日 ,美国心脏病学会(ACC)2012年会报告的一项小规模试验性研究证明,稳定性冠心病患者在经皮冠状动脉介入治疗(PCI)中如用裸金属支架治疗,加用宾达利(bindarit)可显著改善6个月后的血管造影结果。宾达利是一种口服抗炎药,可选择性抑制单核细胞趋化蛋白;与安慰剂组相比,宾达利治疗可显著减少置入裸金属支架后的支架内晚期丢失。   意大利哥伦布医院Antonio Col

同单纯置入BMS相比DEB预扩后置入BMS无临床效果优势(DEB-AMI研究)

    来自荷兰和意大利的DEB-AMI试验6个月随访发现,药物洗脱球囊预扩后置入裸金属支架(DEB加BMS)后造影结果并不优于单纯置入裸金属支架(BMS);药物洗脱支架(DES)造影结果比BMS或DEB加BMS更好。此外,和BMS相比,支架置入前以DEB预扩会导致更多的支架贴壁不良和覆盖不良,不过,该两种情况发生仍少于置入DES的患者。研究4月11日在线发表于《美国心脏病学会杂志》(

历史性一刻,BMS单抗Opdivo强势来袭,中国**款提交上市申请的PD-1/PD-L1类药物

11月2日,百时美施贵宝提交了Opdivo的上市申请(JXSS1700015)得到了CDE受理。而Opdivo也将历史性的成为中国第一款提交上市申请的PD-1/PD-L1类药物!

Oncotarget:PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭

尽管针对PD-1 / PD-L1免疫检查点的抗体近年来在抗癌治疗方面取得了令人瞩目的成就。 相比之下,目前仍没有针对PD-1 / PD-L1免疫检查点的小分子化合物的报道,相比于经静脉注射给药或皮下注射给药方式,小分子独有的口服给药方式会极大提高患者的依从性。近日波兰学者在Oncotarget杂志中报道了几种小分子能够减轻PD-1 / PD-L1免疫检查点介导的Jurkat T淋巴细胞衰竭,这两种

BMS拟将其糖尿病药物股份以30亿美元出让AZ

12月18日,《华尔街日报》报道说,百时美施贵宝(BMS)在一项交易中打算将其与阿斯利康(AZ)合伙经营的糖尿病药物股份以30多亿美元的价值出让给该英国制药商。百时美施贵宝上个月已宣布将不再进行糖尿病、丙型肝炎及神经系统疾病新药的研究与开发,但对通过利用自身免疫系统来抗击癌症的药物将增加研发投入。那次重新调整使人们推测百时美施贵宝将寻求出让其与阿斯利康合资经营的糖尿病药物的非美国股份。百时美施贵宝